161 related articles for article (PubMed ID: 2877605)
1. Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995).
Barnard LB; Grantham WG; Lamberton P; O'Dorisio TM; Jackson IM
Ann Intern Med; 1986 Dec; 105(6):856-61. PubMed ID: 2877605
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.
Lamberts SW; Uitterlinden P; Verschoor L; van Dongen KJ; del Pozo E
N Engl J Med; 1985 Dec; 313(25):1576-80. PubMed ID: 2866445
[TBL] [Abstract][Full Text] [Related]
4. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
Lamberts SW; Uitterlinden P; del Pozo E
J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
[TBL] [Abstract][Full Text] [Related]
5. Acute and long-term effects of SMS 201-995 in acromegaly.
Lamberts SW; del Pozo E
Scand J Gastroenterol Suppl; 1986; 119():141-8. PubMed ID: 2876498
[TBL] [Abstract][Full Text] [Related]
6. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.
Chiodini PG; Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Petroncini M; Liuzzi A; del Pozo E
J Clin Endocrinol Metab; 1987 Mar; 64(3):447-53. PubMed ID: 2880861
[TBL] [Abstract][Full Text] [Related]
7. Effective long-term treatment of acromegaly with a long-acting somatostatin analogue (SMS 201-995).
Sandler LM; Burrin JM; Williams G; Joplin GF; Carr DH; Bloom SR
Clin Endocrinol (Oxf); 1987 Jan; 26(1):85-95. PubMed ID: 2879656
[TBL] [Abstract][Full Text] [Related]
8. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly.
Plewe G; Beyer J; Krause U; Neufeld M; del Pozo E
Lancet; 1984 Oct; 2(8406):782-4. PubMed ID: 6148524
[TBL] [Abstract][Full Text] [Related]
9. Role of a long-acting somatostatin analogue (SMS 201-995) in the treatment of acromegaly.
Jackson IM; Barnard LB; Lamberton P
Am J Med; 1986 Dec; 81(6B):94-101. PubMed ID: 2879453
[TBL] [Abstract][Full Text] [Related]
10. Long-term management of acromegaly with sandostatin.
Tolis G
Horm Res; 1988; 29(2-3):112-4. PubMed ID: 2900189
[TBL] [Abstract][Full Text] [Related]
11. The somatostatin analogue SMS 201-995 in acromegaly: prolonged, preferential suppression of growth hormone but not pancreatic hormones.
George SR; Hegele RA; Burrow GN
Clin Invest Med; 1987 Jul; 10(4):309-15. PubMed ID: 2888554
[TBL] [Abstract][Full Text] [Related]
12. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients.
Christensen SE; Weeke J; Orskov H; Møller N; Flyvbjerg A; Harris AG; Lund E; Jørgensen J
Clin Endocrinol (Oxf); 1987 Sep; 27(3):297-306. PubMed ID: 2892599
[TBL] [Abstract][Full Text] [Related]
13. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
Barkan AL; Kelch RP; Hopwood NJ; Beitins IZ
J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720
[TBL] [Abstract][Full Text] [Related]
14. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
15. Effect of a single administration of somatostatin analogue (SMS 201-995) on GH, TSH and insulin secretion in patients with acromegaly.
Horikawa R; Takano K; Hizuka N; Asakawa K; Shibasaki T; Masuda A; Shizume K
Endocrinol Jpn; 1986 Dec; 33(6):743-9. PubMed ID: 2884093
[TBL] [Abstract][Full Text] [Related]
16. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.
Lamberts SW; Zweens M; Klijn JG; van Vroonhoven CC; Stefanko SZ; Del Pozo E
Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748
[TBL] [Abstract][Full Text] [Related]
17. Acromegaly from ectopic growth hormone-releasing hormone secretion by a malignant carcinoid tumor. Successful treatment with long-acting somatostatin analogue SMS 201-995.
Barkan AL; Shenker Y; Grekin RJ; Vale WW
Cancer; 1988 Jan; 61(2):221-6. PubMed ID: 2891432
[TBL] [Abstract][Full Text] [Related]
18. The effect of minisomatostatin on anomalous growth hormone responses in acromegaly.
Pieters GF; Smals AE; Smals AG; von Gennep JA; Kloppenborg PW
Acta Endocrinol (Copenh); 1987 Apr; 114(4):537-42. PubMed ID: 2883797
[TBL] [Abstract][Full Text] [Related]
19. The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly.
Comi RJ; Gorden P
J Clin Endocrinol Metab; 1987 Jan; 64(1):37-42. PubMed ID: 2878009
[TBL] [Abstract][Full Text] [Related]
20. Glucose tolerance during long term treatment with a somatostatin analogue.
Verschoor L; Lamberts SW; Uitterlinden P; Del Pozo E
Br Med J (Clin Res Ed); 1986 Nov; 293(6558):1327-8. PubMed ID: 2878704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
